Form 4 for XFOR X4 Pharmaceuticals, Inc
Accepted 2023-11-02 00:00:00 ET · period of report 2023-10-31 · accession 0001628280-23-036459 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-02 | 2023-10-31 | XFOR | DiBiase Mary | COO | A - Grant | $0.00 | +230.6K | 378.5K | +156% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-31 | A | A | 230,645 | $0.00 | 378,539 | D | — | — | (F1) Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. |